Medeze Group

Medeze Group EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is -452.47. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 238.44 — a change of -289.76% (lower).

EV/FCF

-452.47

YoY

-289.76%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Medeze Group is 2025 -452.47 . EV/FCF (Enterprise Value to Free Cash Flow) of Medeze Group was 2024 238.44 . It decreases by -289.76% lower compared to the previous year.

The Medeze Group EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
37.00 THB
Jan 1, 2019
44.97 THB
Jan 1, 2020
66.57 THB
Jan 1, 2021
63.78 THB
Jan 1, 2022
28.29 THB
Jan 1, 2023
26.16 THB
Jan 1, 2024
238.44 THB
Jan 1, 2025
-452.47 THB
The Medeze Group EV/FCF history
YEAREV/FCFYoY
-452.47-289.76%
238.44+811.60%
26.16-7.55%
28.29-55.64%
63.78-4.19%
66.57+48.04%
44.97+21.53%
37.00+37.97%
26.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

EV/FCF (Enterprise Value to Free Cash Flow) of Medeze Group is -452.47 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Medeze Group changed from 238.44 to -452.47, representing a -289.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Medeze Group since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Medeze Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medeze Group

All Key Metrics — Medeze Group